RandyW Posted September 18, 2008 Share Posted September 18, 2008 Pfizer Reports Encouraging Results From Phase II Lung Cancer Trial Posted on: Tuesday, 16 September 2008, 12:00 CDT Pfizer has announced updated safety and efficacy results from a Phase II, randomized, non-comparative study surrounding its investigational compound, CP-751,871, in patients with non-small cell lung cancer. Results from a Phase II, randomized, non-comparative study showed that 54% of patients with stage III/IV treatment-naive NSCLC receiving the combination CP-751,871 plus carboplatin and paclitaxel (n=97) experienced objective responses. The response rate was 41% in patients treated with carboplatin and paclitaxel alone (n=53). In addition, 78% of a subset of patients with squamous cell carcinoma (n=9) and 57% of a subset of patients with adenocarcinoma (n=28) receiving 20mg/kg of CP-751,871 plus carboplatin and paclitaxel experienced objective responses. Response rates were 46% and 25%, respectively, for squamous cell (n=12) and adenocarcinoma patients (n=20) receiving carboplatin and paclitaxel alone. No response advantage with CP-751,871 was seen in a subset of patients with undifferentiated tumors. Patients who received CP-751,871 20mg/kg showed the greatest improvement in progression-free survival (PFS). PFS was defined as either the length of time before the cancer progressed or death. Antonio Gualberto, director and global clinical leader (oncology), Pfizer global R&D, said: "These data provide greater insight into the potential relationship between tumor histology and response to CP-751,871 observed in the clinical studies. Furthermore, the results support the global Phase III clinical trial program for CP-751,871 in NSCLC." Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.